Effects of MDMA-like Substances in Healthy Subjects

MDMA

Brief Summary

The serotonin (5-HT) and oxytocin releaser and so-called "empathogen" 3,4-methylenedioxymethamphetamine (MDMA) acutely produces positive feelings, empathy, and trust. MDMA is used recreationally (ecstasy), as research tool to study 5-HT and oxytocin function, and is investigated for MDMA-assisted psychotherapy. MDMA is metabolized in part (10%) to the psychoactive metabolite 3,4-methylenedioxyamphetamine (MDA) which itself is also a recreational substance and has also been used to assist psychotherapy in the past. The present study aims to describe and directly compare for the first time the effects of MDMA and MDA in the same healthy volunteers and using modern psychological and psychometric tests. Additionally, although amphetamines including MDMA and MDA induce mainly positive subjective effects they may also produce negative subjective drug effects including anxiety in particular at the onset of the subjective response and the rapid onset of euphoria may increase the risk of abuse. Additionally, blood pressure may increase rapidly at drug onset. A possible solution to mitigate anxiety, abuse-related rapid euphoria increases and/or rapid blood pressure changes at onset consist of slowing the onset of the drug effect by using a slow-release formulation of MDMA. In the present study, the investigators will characterize the effects of lysine-MDMA and lysine-MDA and compare their effects with MDMA/MDA to test the concept of attenuated effects across both substances.

Intervention / Treatment

Double-blind, placebo-controlled, 5-period cross-over design with four active substance conditions (equimolar doses of psychoactive substance) and placebo: 1. MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base) 2) MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base) 3) lysMDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base) 4) lysMDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base) 5) Placebo
  • 3,4-methylenedioxymethamphetamine (DRUG)
    A moderate dose of 100 mg MDMA will be administered.
  • 3,4-methylenedioxyamphetamine (DRUG)
    A moderate dose of 93.9 mg MDA will be administered.
  • lysine-3,4-methylenedioxymethamphetamine (DRUG)
    A moderate dose of 171.7 mg lysine-MDMA will be administered.
  • lysine-3,4-methylenedioxyamphetamine (DRUG)
    A moderate dose of 165.6 mg lysine-MDA will be administered.
  • Placebo (OTHER)
    Placebo (Mannitol)

Condition or Disease

  • Healthy

Phase

  • Phase 1

    • Study Design

    Study type: INTERVENTIONAL
    Status: Recruiting
    Study results: No Results Available
    Age: 18 Years to 65 Years
    Enrollment: 24 (ESTIMATED)
    Funded by: Other
    Allocation: Randomized
    Primary Purpose: Basic Science

    Masking

    TRIPLE:
    • Participant
    • Care Provider
    • Investigator

    Clinical Trial Dates

    Start date: Dec 01, 2021 ACTUAL
    Primary Completion: Dec 31, 2023 ESTIMATED
    Completion Date: Dec 31, 2023 ESTIMATED
    Study First Posted: Apr 19, 2021 ACTUAL
    Last Updated: Dec 07, 2021

    Sponsors / Collaborators

    Lead Sponsor: University Hospital, Basel, Switzerland
    Lead sponsor is responsible party
    Responsible Party: N/A

    Location

    Basel, Basel-Stadt, Switzerland

    3,4-methylenedioxymethamphetamine (MDMA) is used as recreational substance (Ecstasy), research tool to stimulate serotonin (5-HT) and oxytocin release and study associated mood states, and as a potential therapeutic substance to enhance psychotherapy for post-traumatic stress disorder. MDMA is an amphetamine derivative which, unlike prototypical amphetamines, predominantly enhances serotonergic neurotransmission via release of 5-HT through the SERT and it less potently also releases dopamine and norepinephrine through the DA transporter and NE transporter, respectively. Furthermore, MDMA is known to trigger oxytocin release which may contribute to its effects to increase trust, prosociality, and enhance empathy. MDMA is therefore referred to as an "entactogen" or "empathogen". MDMA is currently the only empathogen investigated in substance-assisted psychotherapy but other substances including the MDMA-metabolite 3,4-methylenedioxyamphetamine (MDA) have been used in the past or may be used in the future.

    Aim 1: MDA may exert greater perceptual psychedelic-like effects due to a more potent binding to the serotonin 5-HT2A receptor, and it may also act longer than MDMA partly due to a longer plasma half-life. However, effects of MDMA and MDA have never been compared directly in the same study in humans and there is only one modern study that characterized MDA in humans. Therefore, the present study aims to describe and directly compare for the first time the effects of MDMA and MDA in the same healthy volunteers using modern and sensitive psychological and psychometric tests.

    Aim 2: Additionally, although amphetamines including MDMA and MDA induce mainly positive subjective effects they may also produce negative subjective drug effects including anxiety in particular at the onset of the subjective response and the rapid onset of euphoria may increase abuse liability. Additionally, blood pressure may increase rapidly at drug onset. A possible solution to mitigate anxiety, abuse-related rapid euphoria increases and/or rapid blood pressure changes at onset consist of slowing the onset of the drug effect by using a slow-release formulation of MDMA/MDA. Alternatively, amphetamines can be linked to the endogenous amino acid lysine forming inactive lysine-amphetamine which then liberates the active amphetamine slowly in the circulation via plasma peptidases. This approach has been implemented with the medication Lisdexamfetamine, which combines lysine with d-amphetamine. In the present study, the investigators will similarly characterize the effects of lysine-MDMA and lysine-MDA to test for attenuated effects across both substances in comparison with MDMA/MDA.

    Using a two-factorial study design with four active substance conditions (MDMA vs. MDA and lysine-MDMA vs. lysine-MDA) the investigators will be able to test differences between MDMA and MDA (with and without lysine) as well as between lysinated a non-lysinated substance (regardless of active substance) in the same study and with high statistical power and within one study addressing two aims.

    Participant Groups

    • MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)

    • MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)

    • lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)

    • lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)

    • Placebo

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 65
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    1. Age between 18 and 65 years old
    2. Sufficient understanding of the German language
    3. Understanding of procedures and risks associated with the study
    4. Willing to adhere to the protocol and signing of the consent form
    5. Willing to refrain from the consumption of illicit psychoactive substances during the study
    6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions to the end of the study days
    7. Willing not to operate heavy machinery within 48 hours after substance administration
    8. Willing to use double-barrier birth control throughout study participation
    9. Body mass index between 18-29 kg/m2

    Exclusion Criteria:

    1. Chronic or acute medical condition
    2. Current or previous major psychiatric disorder
    3. Psychotic disorder or bipolar disorder in first-degree relatives
    4. Hypertension (\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
    5. Hallucinogenic substance or MDMA use more than 20 times or use of any illicit substance within the previous two months (not including cannabis)
    6. Pregnancy or current breastfeeding
    7. Participation in another clinical trial (currently or within the last 30 days)
    8. Use of medication that may interfere with the effects of the study medication
    9. Tobacco smoking (\>10 cigarettes/day)
    10. Consumption of alcoholic beverages (\>20 drinks/week)

    This clinical trial is recruiting

    Are you interested in participating in this trial or others? We'd love to help.

    Primary Outcomes

    • Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale from 0 - 100 percent with higher scores representing more intense effects

    • Assessed 18 times on each study day via blood samples

    • Assessed 18 times on each study day via blood samples

    Secondary Outcomes

    • Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely"

    • 5 Dimensions of Altered States of Consciousness (5D-ASC) consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects

    • Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")

    • Assesses the degree of psychological insight caused by a psychedelic experience through 14-items to be answered on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")

    • Assessed 20 times on each study day via systolic and diastolic blood pressure

    • Assessed 20 times on each study day via heart rate

    • Assessed 20 times on each study day via tympanic body temperature

    • Assessed 7 times on each study day via pupil diameter

    • Assessed one time on each study day via ECG (QT-time)

    • Assessed 5 times on each study day via blood samples

    • Assessed one time on each study day via Face Emotion Recognition Task (FERT).

    • Assessed one time on each study day via Multifaceted Empathy Test (MET).

    • The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the "big five": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from "completely disagree" to "fully agree".

    • The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").

    • The SPF defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.

    • The HEXACO personality inventory is a six-dimensional model of human personality with 100 items.The six factors are: Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness and Openness to Experience. The HEXACO uses a 5-point Likert scale ranging from "completely disagree" to "fully agree".

    • The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".

    More Details

    NCT Number: NCT04847206
    Acronym: MDMA-like
    Other IDs: BASEC 2021-00405
    Study URL: https://clinicaltrials.gov/study/NCT04847206
    Last updated: Sep 29, 2023